News

Olympia Pharmaceuticals | 503B Outsourcer | 503A Compounding Pharmacy

Market 50/100How we got 50/100Source tierUnclassified sourceTier ceiling50/100Independent sourcesnot recordedPublished score50/100Scored at the ceiling for a unclassified source source — it cannot go higher. The number is the source page’s own score, hard-capped at the tier ceiling; corroboration is recorded but cannot lift a score past that cap. Under 40 a claim goes to review instead of publication. Full methodology →
July 28, 2026↗ source

Olympia Pharmaceuticals, a FDA-registered 503B outsourcing facility, has expanded its compounding capabilities to include a wide array of therapeutic peptides and injectable nutrients. The company highlights its ability to ship these medications nationwide for office use, bypassing traditional supply chain shortages. Their catalog includes popular peptides like GLP-1 agonists, BPC-157, and various growth hormone secretagogues, positioning them as a key supplier for the weight management and longevity sectors.

Related peptides

BPC-157TB-500IpamorelinCJC-1295GLP-1 receptor agonistsGlutathioneGLP-1C-peptideLongevityGLP-1 AgonistsBPC-157 / TB-500 BlendGLP-1 receptor agonistTherapeutic peptidesGLP-1R
We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.